Comment on “Pretreatment Hepatitis C Virus NS5ANS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

Abstract EN

We very much enjoyed reading the recently published article by Aldunate et al.

[1] in which the authors evaluated the presence of naturally occurring NS5A and NS5B resistance-associated substitutions (RASs) among drug-naïve patients who were chronically infected with Hepatitis C virus (HCV) genotype 1 in Montevideo, Uruguay.

The frequency of targeted RASs in this study is estimated based on 31 HCV patients conveniently recruited from referees to a gastroenterology clinic in Montevideo, Uruguay.

The authors found that naturally occurring NS5A and NS5B RASs were present in 8% and 19.2% of their sample, respectively.

This finding is important as it is the first evidence for the presence of NS5A and NS5B RASs in Montevideo, Uruguay.

However, we think that there are some points that should be considered about the results’ validity and generalizability.